Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
Panagiota Nikolaou, Nikolaos Mylonas, Manousos Makridakis, Marina Makrecka‐Kuka, Aikaterini Iliou, Stelios Zerikiotis, Panagiotis Efentakis, Stavros Kampoukos, Nikolaos Kostomitsopoulos, Reinis Vilšķe̅rsts, Ignatios Ikonomidis, Vaia Lambadiari, Coert J. Zuurbier, Agnieszka Latosińska, Antonia Vlahou, George Dimitriadis, Efstathios K. Iliodromitis, Ioanna Andreadou
Topics & Concepts
EmpagliflozinCardioprotectionPharmacologyDapagliflozinEMPAMedicineWortmanninOxidative stressDiabetes mellitusIschemiaInternal medicineType 2 diabetesChemistryEndocrinologyBiochemistryPhosphorylationProtein kinase BMineralogyElectron microprobeDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerPancreatic function and diabetes